ERBB2 and breast cancer: This is also supported by observations in the GIADA trial that found the combination of a basal-like intrinsic subtype and high TILs could predict pCR after neoadjuvant treatment with chemotherapy, immune checkpoint inhibition, and endocrine therapy in premenopausal women with aggressive HR-positive (ER and/or PR ≥ 10%)/HER2-negative breast cancer [46].